Autoantibodies in COVID-19, a possible role in the pathogenesis of the disease

Ther Apher Dial. 2023 Oct;27(5):882-889. doi: 10.1111/1744-9987.14004. Epub 2023 May 22.

Abstract

Objectives: In this study, we investigated whether SARS-CoV-2 stimulates autoantibody production.

Methods: The study included 91 patients hospitalized due to COVID 19, with no previous history of immunological diseases. Immunofluorescence assays were performed to detect antinuclear antibodies (ANAs) and antineutrophil cytoplasmic antibodies (ANCAs), along with tests for specific autoantibodies.

Results: The median age (57% male) was 74 years (range 38-95 years). Autoantibodies were positive in 67 (74%), ANA in 65 (71%), and ANCA in 11 (12%) patients. Female gender (p = 0.01), age (p = 0.005), and Charlson comorbidity index (p = 0.004) were significant predictors for the development of ANA/ANCA antibodies (p = 0.004). Nuclear mitotic apparatus (NuMA)-like, positivity was the strongest predictor of acute kidney injury (AKI), together with noninvasive ventilation and eGFR (χ2 = 49.01, P < 0.001).

Conclusion: Positive autoantibodies in a large proportion of patients suggest a role of autoimmunity in the pathophysiology of acute COVID-19 disease. NuMA was the strongest predictor of AKI.

Keywords: Coronavirus disease-2019; acute kidney injury; antineutrophil cytoplasmic antibody; antinuclear antibody; rehospitalization.

MeSH terms

  • Acute Kidney Injury*
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Antineutrophil Cytoplasmic
  • Autoantibodies
  • COVID-19*
  • Female
  • Humans
  • Male
  • Middle Aged
  • SARS-CoV-2

Substances

  • Autoantibodies
  • Antibodies, Antineutrophil Cytoplasmic